Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.

Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.

Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.

Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.

Eisai

Eisai Co. Ltd. and Eli Lilly and Co. on April 8 said they still plan to seek accelerated U.S. approval for experimental Alzheimer’s drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.

U.S. Medicare limits coverage for Biogen’s Alzheimer’s drug Published April 7, 2022; 7:40 PM EDT By Deena Beasley April 7 (Reuters) – The U.S. government health plan for people age […]

Japan’s Eisai Co. Ltd. will surrender the company’s rights to share profit from Aduhelm – the Alzheimer’s treatment drug jointly developed with U.S. partner Biogen Inc. – and instead receive sales royalties, the companies said on March 14.

Patient groups mounted a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the March 13 morning political shows.

Cassava Sciences warned that the U.S. Food and Drug Administration might order a clinical hold on the company’s studies for the Alzheimer’s drug simufilam in 2022 after learning that two of its competitors received hold orders for similar research efforts. 

Pharmaceutical giant Roche and subsidiary Genentech announced a new Phase III clinical trial for gantenerumab, a monoclonal anti-amyloid antibody that is designed to treat Alzheimer’s disease.